Genomic differences in breast cancers in African American women identified
the ONA take:
Differences in breast cancer recurrence and survival between African American women and white women are well established; however, what drives those differences is not well known.
In this paper, published online in the Journal of Clinical Oncology, investigators describe genomic differences in the tumors of the two groups of women that may explain those disparities.
The impact of socioeconomic factors such as income, health insurance, and access to health services contributes to disparities in recurrence and survival for African American women with breast cancer. Those factors, however, do not explain the whole difference.
The investigators analyzed whole-exome sequencing data from the National Cancer Institute’s Cancer Genome Atlas culled from the tumors of 105 African American women and 664 white women whose breast cancers were diagnosed between 1988 and 2013.
The five most prevalent tumor-specific mutations were the same for both groups, but more African American women’s tumors were driven by the TP53 mutation and the PIK3CA mutation was more common in the white women’s tumors.
Additional factors were found that suggest more aggressive cancers, such as prevalence of the basal-like and mesenchymal stem-like subtypes and the number of mutations within each tumor, were greater in African American women’s tumors.
Basal subtype tumors or those driven by the TP53 mutation were factors in faster tumor recurrence, and also more likely among African American women.
Differences in breast cancer recurrence and survival between African American women and white women are well established.
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Cancer Risk Not Increased by Childhood Exposure to Diagnostic Radiation
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Immune Thrombocytopenia (Fact Sheet)
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|